跳到正文
原文
NEJM 新英格兰医学杂志· Luke J. LaffinCleveland Clinic Coordinating Center for Clinical Research, ClevelandStephen J. NichollsVictorian Heart Institute, Melbourne, VIC, AustraliaRussell S. ScottNew Zealand Clinical Research, Christchurch, New ZealandPeter M. CliftonRoyal Adelaide Hospital, Adelaide, SA, AustraliaRenate KoopsAotearoa Clinical Trials, Auckland, New ZealandAshish SarrajuCleveland Clinic Coordinating Center for Clinical Research, ClevelandShweta SinghCRISPR Therapeutics, BostonQiuqing WangKathy WolskiCleveland Clinic Coordinating Center for Clinical Research, ClevelandHuansheng XuJen NielsenNaimish PatelJason M. DuranCRISPR Therapeutics, BostonSteven E. NissenCleveland Clinic Coordinating Center for Clinical Research, Cleveland·· 2026-08-28AI 评分51

靶向 ANGPTL3 的 CRISPR-Cas9 基因编辑 CTX310 持久性研究

Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310

AI 导读

NEJM 发表题为《Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310》的通讯文章,刊于第 395 卷第 13 期第 1343-1345 页,作者团队来自 Cleveland Clinic、CRISPR Therapeutics 等机构。

来源:NEJM 新英格兰医学杂志 · nejm.org